Determining disease severity in patients with COVID-19

Timothy Alcorn co-authored a paper published by Lab on a Chip titled, “Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19†”.  Dr. Alcorn is the Director of Medical Devices and Diagnostics for Latham BioPharm Group and was consulted for his expertise in this area.

This paper was also recently referenced in a news release by NYU on June 3, 2020, read more here.

Learn more about Timothy Alcorn

Lab Chip, 2020, Advance Article
First published June 3, 2020